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Investigating the Effects of Increasing Anti-AMA1, Anti-
MSP1, and Anti-MSP2 In Preventing Malaria Incidence 
April Skipper, College of Natural and Health Sciences, Southeastern 
University 
                    
Abstract: 
Malaria is a life-threatening illness that 3.2 billion people, half of the world's population, are at 
risk of contracting. In 2015, there were 214 million malaria cases and 438,000 deaths caused by 
the disease. It is caused by Plasmodium parasites which infect humans through the bite of the 
Anopheles mosquito. The four species of Plasmodium that are known to cause malaria are P. 
falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. The symptoms of malaria greatly 
resemble symptoms of a common cold, so accurate diagnosis can be a challenge. Symptoms 
commonly include fever, headache, vomiting, but can progress to include anemia, respiratory 
distress, cerebral problems, multi-organ failure, and death in cases of severe malaria.  
The most available and effective treatment for malaria currently is artemisinin-based 
combination therapy (ACT). Due to widespread misdiagnosis and overuse of effective drugs, 
many strains of Plasmodium have become resistant to common antimalarial drugs. Multi-drug 
resistant strains may become a larger problem, so development of an effective malaria vaccine is 
an important step in malaria control and hopeful eradication.  
In some individuals, immunity against severe malaria can be acquired by the age of 5 years. The 
rapid development of immunity against severe malaria shows that a vaccine targeting young 
children is feasible. The exact immunological basis of this protective immunity is still unknown. 
It was seen through epidemiological studies that the antibody anti-AMA1 was present in a larger 
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proportion in immune individuals than in non-immune individuals. It was also found that 
merozoite surface proteins 1 and 2 (MSP1 and MSP2) seem to be major targets of antibody-
mediated complement-dependent inhibitory activity. This study aims to test whether these 
antibodies do successfully prevent malaria infection in mouse models, both individually and in 
combination. 
Specific Aims: 
1. To determine whether an increase in anti-AMA1, anti-MSP1, and anti-MSP2 antibodies 
independently decrease the incidence of malaria in mouse models. 
 -Mouse models will be injected with one of these three antibodies 
 -Mice will be put in a container where Plasmodium-carrying mosquitoes are added 
 -Blood smears will be taken from mice and analyzed for the presence of Plasmodium 
2. To determine whether an increase in a combination of anti-AMA 1, anti-MSP1, and anti-
MSP2 decrease the incidence of malaria in mouse models. 
 -Mouse models will be injected with a combination of the three antibodies 
 -Mice will be put in a container where Plasmodium-carrying mosquitoes are added 
 -Blood smears will be taken from mice and analyzed for the presence of Plasmodium 
3. To determine whether injection of an antibody formulation in pregnant mice will induce 
malaria immunity in their pups. 
 -Pregnant mouse models will be injected with the most effective antibody combination 
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 -Mouse pups will be born and put in a container where Plasmodium-carrying mosquitoes 
 are added 




















As of January 2016, 3.2 billion people are at risk for contracting malaria.1 These people live in 
areas of high malaria transmission, which includes 106 countries.2 In 2015 alone there were 214 
million malaria cases with 438,000 deaths.1 Of these 438,000 deaths, 78% of them occurred in 
children under the age of 5.3 Although the death rate from malaria is steadily decreasing (Figure 
1),  malaria is still the leading cause of death and disease in many developing countries, with 
young children and pregnant women being the most affected groups due to their 
immunocompromised status.2  
 
 
Figure 1. Percentage decrease in malaria death rate between 2000 and 
2015.59 
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Of the countries affected, Sub-Saharan Africa carries a high share of the malaria burden. In 2015, 
88% of all malaria cases and 90% of malaria deaths were in this area alone.4 Though malaria is 
still such a large health burden to half of the world's population, it is a preventable and curable 
disease. Many countries have eradicated or significantly reduced the incidence of malaria, which 






Figure 2. Estimated number of malaria cases in 2000 and 2015 
by region.60 As shown here, most continents have significantly 
reduced their malaria incidence rates. Africa still carries a very 
large portion of the malaria burden, followed by South-East 
Asia. 
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Why Malaria is Still a Problem: 
Though malaria is preventable and curable, it still remains a large global health problem for 
many reasons. Most affected areas include poor and underdeveloped regions.2 Though malaria is 
treatable, an infected patient would need to be diagnosed and begin treatment very quickly, 
which is nearly impossible in many remote areas.5 Even if the affected patient had access to local 
healthcare, the cost of visiting a physician, diagnostic tests, and medication is likely to be too 
high for the patient's family due to the poverty-stricken areas in which malaria is endemic.  
In addition to these barriers, the symptoms of malaria greatly resemble many other sicknesses 
including the common cold.6 This causes a high level of misdiagnosis, which in the rapidly-
progressing case of malaria, can easily result in death. Finally, malaria still remains a large 
problem due to the scarce availability of drug treatments and other preventative measures in the 
affected areas.5 
Life Cycle of Parasite: 
Malaria is caused by the Plasmodium parasite which is spread to humans through infected female 
Anopheles mosquitoes, serving as malaria vectors.4 There are five species of Plasmodium known 
to cause malaria in humans.7 The first is P. falciparum, which is very prevalent in Sub-Saharan 
Africa, can cause severe malaria due to its rapid multiplication in the blood.8 P. vivax, found 
mainly in Asia, has a dormant liver stage that can reactivate months or years after inoculation in 
the body.8 P. ovale is found in Africa and western Pacific islands, and is similar to P. vivax.8 P. 
malariae has a three-day life cycle and can cause chronic infection that can last an entire 
lifetime.8 Finally, P. knowlesi is found in Asia and has a 24-hour replication cycle, making it 
rapidly progress to severe infection.8  
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The parasite acts on two hosts: humans and the mosquitoes.9 Once the parasite has infected the 
mosquito, the mosquito transmits the parasite to humans through a bite in the form of 
sporozoites.10 In humans, parasites grow and multiply in hepatocytes before moving to 
erythrocytes.10 While inside erythrocytes, parasites continue to grow and begin destroying the 
erythrocytes they occupy, releasing daughter parasites, or merozoites, that then continue with 
this cycle.11 A detailed representation of the Plasmodium life cycle can be seen in Figure 3. 
 
 
As seen in Figure 3, the first step of infection takes place when a parasite-infected female 
Anopheles mosquito bites a human, injecting the parasite's sporozoites into the human host.9 
This then begins the exo-erythrocytic cycle, where the sporozoites travel to the liver and infect 
hepatocytes. Inside hepatocytes, the sporozoites mature into schizonts. After fully maturing, the 
Figure 3. Life cycle of Plasmodium parasite.9 
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schizonts cause the hepatocyte to burst, releasing merozoites into the blood stream. Plasmodium 
vivax and Plasmodium ovale have the special ability of keeping some of the parasite, known here 
as hypnozoites, in the liver cells which can cause a relapse by rupturing and releasing into the 
bloodstream weeks or years later. This is known as a dormant stage.9 
This then begins the erythrocytic stage of the parasite life cycle. In this stage, merozoites 
undergo asexual replication inside erythrocytes.9 As shown in step 5, merozoites are infecting 
red blood cells, where they become immature trophozoites. This is referred to as a ring stage 
because the parasite takes the shape of a ring inside the erythrocyte. The immature trophozoite 
now has two options, it can become a mature trophozoite or a gametocyte. Mature trophozoites 
turn into schizonts, which cause the erythrocyte to rupture, releasing more schizonts into the 
bloodstream. The schizonts then begin the erythrocytic stage again in a cyclical fashion as long 
as there are still erythrocytes to infect.9  
The immature trophozoites that mature into gametocytes enter into a sexual erythrocytic stage.9 
These gametocytes are either male, microgametocytes, or female, macrogametocytes. If an 
infected human host receives a second bite from a female Anopheles mosquito, these male and 
female gametocytes will be ingested by the mosquito and will enter the sporogonic cycle, part C 
in Figure 3, inside the mosquito's stomach.9  
To begin this stage, microgametes enter into the macrogametes, which generates a zygote.9 The 
zygote becomes elongated and gains the ability to move on its own. These qualities give the 
zygote the ability to carry out its next function. At this point, the zygote is referred to as an 
ookinete. This ookinete inserts into the midgut wall of the mosquito, where it develops into an 
oocyst. An oocyst becomes much more round in shape than an ookinete. The oocyst then grows 
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and ruptures, which releases sporozoites into the mosquito host. These sporozoites enter into the 
mosquito's salivary glands, where they are primed and ready to enter a human host with the 
mosquito's next bite.9 
Where Malaria Occurs: 
Malaria transmission is found in tropical and subtropical regions of the world.12 Many of these 
places are poor and underdeveloped communities.2 The main geological factor affecting malaria 
transmission is temperature.12 Anopholes mosquitoes require a relatively warm environment to 
survive and multiply.13 Plasmodium cannot complete its growth cycle in temperatures below 20° 
C.12 Even in countries where malaria is endemic, transmission does not occur or significantly 
decreases during colder seasons, at high altitudes, and in deserts.12 Regions closer to the equator 
have more intense transmission and longer transmission seasons.12  
As mentioned before, Sub-Saharan Africa experiences the bulk of the malaria burden, with 88% 
of all malaria cases in 2015 occurring there.4 In temperate areas of western Europe and the 
United States, public health measures and economic development have eliminated malaria.12 
However, these areas do have Anopheles mosquitoes, so reintroduction of malaria is always a 
risk.12 Areas where malaria transmission occurs can be seen in Figure 4. 





Drugs Against Plasmodium: 
Drugs used to treat P. falciparum malaria target the intraerythocytic stage of the parasite.14 This 
stage of the parasite life cycle is where symptoms first present in an infected patient.14 Three 
broad classes of drugs are used are quinolines, antifolates, and artemisinin-combination 
therapies.14 Quinolines act as hemozoin inhibitors.15 Heme is toxic to Plasmodium, so the 
parasite must use hemoglobin proteolysis for nutrients.15 The Plasmodium food vacuole lyses 
hemoglobin, producing hemozoin.15  
Figure 4. Map of malaria transmission.12 
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Antifolates block the folic acid synthesis pathway by binding to tetrahydrofolate dehydrogenase 
more tightly than to the host enzyme.16 This prevents the parasite from using pyrimidines 
synthesized in the host, forcing it to create its own.14 Artemisinin-combination therapies are 
widely the most commonly used treatment for P. falciparum infection.14 Artemisinins come from 
a Chinese herb called Artemisia annua, and are suspected to work through a mechanism similar 
to that of quinolines, reversing the conversion of heme to hemeozoin.14 They carry out their 
functioning in the parasite mitochondria by forming peroxide bridges.17 Peroxide bridges can be 
cleaved by iron ions to form free radical oxygen species. These species would then go on to 
attack the parasite merozoites.112 Though the three broad classes of antimalarial drugs were 
discussed, there are seven more specific classes, which are seen in Figure 5.61 
 
Figure 5. Seven 
classes of 
antimalarial drugs 
and the structures of 
the compounds in 
each class.61 
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Occurrence of Antibiotic Resistance:  
The first occurrence of antibiotic resistance in malaria drugs occurred in 2000, when mutations 
within P. falciparum conferred resistance to chloroquine in Colombia and Thailand.18 Before this 
resistance, quinolines had been used to fight malaria since the 17th century.18 Chloroquine-
resistant mutations have been spreading throughout most endemic countries since this first 
occurrence.19 In response to this resistance, sulfadoxine-pyrimethamine largely replaced 
chloroquine in areas with chloroquine resistance.20  
Unfortunately, resistance to sulfadoxine-pryimethamine rapidly evolved and now also occurs in 
most endemic regions.20 To counter this resistance, artemisinin-based combination therapies 
began to be largely used.21 These have higher production costs, which is a significant barrier to 
translation into endemic areas.22 Antibiotic resistance in parasite DNA evolves very quickly, so 
development of affordable and effective drugs is a major problem in fighting the spread of the 
disease.23  
The Search for a Vaccine Candidate 
Overview of Vaccine Research: 
In 2007, an official research and development agenda for malaria eradication was established, 
with the goal of completely eradicating the disease.24 One large strategy to achieve this was to 
support the development of a vaccine. Much research has been put in to the search for a malaria 
vaccine, and the vaccine RTS,S/Mosquirix has been the most advanced thus far.25 This vaccine 
protects against P. falciparum and has been approved by the European Medicines Agency 
(EMA) for children aged 6 weeks to 17 months.26  
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In the development of a vaccine, finding the best target, a good production and delivery method, 
and appropriate formulation and adjuvants are very important and has proven difficult.27,28 
Achieving large-scale production of protein antigens with the correct folding is necessary for 
achieving highly specific high titres in humans, which has proven to be another difficult task.29-31 
Escherichia coli, Lactococcus lactis bacterium models, Baculovirus, yeast, plant-based systems, 
and algae are among the many expression systems being used for recombinant antigens.32-37 
Another delivery route being researched is particle-delivery technology.38 This would include the 
use of virus-like particles and nanoparticles.39 An emerging field in vaccine research is using 
DNA vaccine technology, which is still very early in its development.40,41  
Another route being researched is providing immunity through the use of different antigens. 
Most of these are still in the preclinical stage but are being considered for their first test in 
humans.42 Two different recombinant strategies targeting Pfs25 antigen are in phase I clinical 
trials and are the only candidates targeting sexual, sporangonic, or mosquito-stage antigens.43,44 
Even so, these are only a small portion of the many malaria vaccines being tested.45 
RTS,S: 
RTS,S is a vaccine made of a liposome-based adjuvant (AS01) and hepatitis B virus surface 
antigen (HBsAg) virus-like particles that incorporate a portion of the Plasmodium falciparum-
derived circumsporozite protein (CSP) genetically combined with HBsAg.62 If approved by 
regulatory authorities, this vaccine would be used for infants between 6 weeks and 17 months 
old. It also will have been in-the-making for more than 30 years. A timeline listing the major 
events in the creation of RTS,S can be seen in Figure 6. 






RTS,S targets the circumsporozite protein, which plays a large role in maturing the Plasmodium 
oocyst in the midgut of the mosquito.63 Only a small portion of sporozites in the salivary glands 
of the mosquito are inoculated into the bloodstream of the human.63 Due to this parasite 
numerical bottleneck, it is thought that the parasite is most vulnerable to immune attack as it 
switches between the mosquito host and human host.64 This provides a good opportunity to 
induce a novel immune response through active immunization.65 The circumsporozite protein is 
located on the surface of the parasite sporozoite and is responsible for forming a coat on the 
parasite surface.66 
Figure 6. Timeline of the development of RTS,S spanning 
more than 30 years.62 GlaxoSmithKline (GSK) and the Walter 
Reed Army Institute of Research (WRAIR) initiated this 
development in 1984, and the PATH Malaria Vaccine Initiative 
(MVI) was established in 2001. RTS,S entered clinical trial 
Phase III in 2009 and was completed in 2014. 
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In its most recent Phase III clinical trials, RTS,S was evaluated in eight different African 
countries.62 Vaccine efficacy has proven to be modest with varying ranges of efficacy depending 





Figure 7. Vaccine efficacy and impact against clinical malaria 
for Phase III trial in eight African study sites.62 (A) represents 
children aged 5-17 months, and (B) represents infants aged 6-12 
weeks. The R3C group received three doses of RTS,S and a 
control booster dose, while the R3R group received three doses 
and a booster dose of RTS,S. 
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Figure 7 shows final results for the phase III efficacy and safety trial MALARIA-055. This was 
a double-blind, randomized, controlled trial where participants ages 5-17 months or 6-12 weeks 
received either three doses of RTS,S and a booster, three doses of RTS,S and a control vaccine, 
or only control vaccines throughout. It is noted that the number of cases of clinical malaria 
averted had a greater impact in sites with higher malaria burden. Figure 7 shows vaccine 
efficacy and impact against clinical malaria. A Forest plot is shown of efficacy with 95% 
confidence intervals for the group that received four doses of RTS,S (R3R). A bar graph is 
shown for the number of cases averted for groups that received three doses (R3C) and four doses 
(R3R) of RTS,S by site with A representing the 5-17 months age group and B representing 6-12 
weeks age group. Although the vaccine efficacy at some sites is promising, there is still a great 
deal of uncertainty about just how effective RTS,S would be overall due to the large discrepancy 
in efficacy rates across all testing sites. Thus, it remains necessary to explore more vaccine 
candidates. 
Experimental Design 
Background: Epidemiological studies have shown that immunity against severe malaria is 
acquired by the age of 5 years in areas with intense malaria transmission.46-48 In these same 
areas, immunity against uncomplicated malaria is usually achieved by adulthood, while 
immunity against asymptomatic infection is never achieved.49,50 The rapid acquisition of 
immunity against severe malaria supports the claim that a malaria vaccine targeting young 
children could be very effective. Antigens found on the surface of infected erythrocytes (iRBC) 
inhibit sequestration of  iRBCs, and promote opsonization of iRBCs for phagocytic attack.51-53 It 
was found through epidemiological data that antibodies to apical membrane antigen 1 (AMA1) 
significantly reduce the odds of developing severe malaria in children 0-5 years old, suggesting 
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that it is a viable vaccine candidate for young children.54 It is also suggested that passively 
transferred maternal IgG contributes to protective immunity.54  
The mechanism through which many antibodies mediate immunity to malaria has long barred 
vaccine development. It has recently been found that acquired human anti-malarial antibodies 
promote complement deposition on the Plasmodium merozoite.55 This plays a large role in 
inhibiting erythrocyte invasion through C1q fixation and activation of the classical complement 
pathway.55 Epidemiological data suggests that inhibitory activity was mainly mediated by C1q 
fixation with merozoite surface proteins 1 and 2 (MSP1 and MSP2) being the major targets.55 
This suggests that antibody-mediated complement-dependent inhibitory activity could be 
induced by immunization with a merozoite surface-protein vaccine.55  
Apical Membrane Antigen 1: 
Apical membrane antigen 1 (AMA1) is a transmembrane protein in the Apicomplexa phylum 
and is thought to help shape the tight junction formed between the Plasmodium parasite apex and 
the host cell.67-73 This tight junction formed between the Plasmodium parasite and host 
erythrocyte can be seen in Figure 8. AMA1 has a cytoplasmic tail which is reported to bind to 
aldolase. The ectodomain of AMA1 binds in parasite extracts to the rhoptry neck 2 (RON2) 
protein.70-72 RON2 proteins localize at the tight junction where the parasite inserts into the host 
cell membrane.  
Antibodies that inhibit the AMA1-RON2 interaction reduce host cell invasion by Plasmodium 
merozoites.74-76 It was shown that AMA1-deficient merozoites displayed a three- to five-fold 
decrease in overall invasion efficiency in penetrating host cell erythrocytes.77 Also, a large body 
of work shows that antibodies to AMA1 are effective in blocking erythrocyte invasion.78-80 This 
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effect may also reduce sporozoite invasion of hepatocytes.81 A study found that strategies 
targeting only AMA1 would not be effective.77 Thus, a vaccine targeting a combination of 




Merozoite Surface Protein 1: 
Merozoite surface protein 1 (MSP1) is found on the surface of the merozoite in the Plasmodium 
falciparum parasite and is implicated in the process of merozoite invasion of the erythrocyte.83,84 
Among the several events driving erythrocyte invasion is merozoite binding to sialic acid 
residues on erythrocyte receptors.117 MSP1 is required for attachment of merozoites to the 
Figure 8. A Plasmodium merozoite (Mz) forming a tight 
junction (TJ) with a host red blood cell (RBC) in order to 
invade the RBC and continue its parasitic life cycle.82 
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specific host receptor named Band 3.118 MSP1 is also required for normal parasitic 
development.119 MSP1 is synthesized as a precursor and then processed in two steps. The 
primary step produces a complex of four fragments present on the merozoite surface, and the 
secondary step at invasion results in the shedding of the complex from the surface. After this 
shedding, only the C-terminal domain remains on the parasite surface by a 
glycosylphophatidylinositol moiety.85 This C-terminal domain remaining is well conserved and 
contains two epidermal growth factor-like (EGF-like) domains that play a large role in merozoite 
invasion in erythrocytes. Thus, antibodies that target this EGF-like domain on the C-terminal 
motif of MSP1 would prevent host invasion.116 
A ribbon diagram of the C-terminal domain containing EGF-like domains from Plasmodium 
falciparum MSP1 can be seen in Figure 9. Several studies show that the protective immune 
responses against P. falciparum MSP-1 in mice are directed against the C-terminal domain.86-91A 
possible mechanism for inhibition of merozoite invasion has been proposed to be through the 
inhibition of MSP-1 processing by conformation-specific antibodies.92 
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Merozoite Surface Protein 2: 
Merozoite surface protein 2 (MSP2) is a blood-stage protein that is essential for completion and 
viability of the Plasmodium life cycle.94-97 It has been found to induce specific antibodies that are 
active against parasite merozoites and are associated with protection in malaria endemic areas.98-
100 It is a glycosylphosphatidylinositol-anchored protein found on the merozoite surface and has 
200-250 amino acids, all encoded by one exon on chromosome 2. MSP2 has conserved N and C 
terminal (C) regions flanking a polymorphic central repeat region.101 A non-repeat semi-
conserved dimorphic (D) region defines two allelic families of MSP2. These families are 3D7 
and FC27.102  
A specific semi-immune antibody against MSP2 is cytophillic IgG3. IgG3 along with IgG1 
antibodies are thought to play a role in antibody-mediated mechanisms of parasite clearance.103-
106 In a phase I  clinical trial, a recombinant vaccine candidate containing both 3D7 and FC27 
Figure 9. Ribbon-diagram 
representation of the structure of the 
EGF-like domain from the Plasmodium 
falciparum merozoite surface protein 
1.93 
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forms of MSP2 showed that subjects elicited antibodies that were specific for both forms of 
MSP2 and active in inhibiting parasite growth in antibody-dependent cellular inhibition.107 Thus, 
both allelic forms of MSP2 remain a possible vaccine candidate in a combination vaccine. The 
crystal structure of anti-MSP2 fragment complexed with both allelic forms of MSP2 can be seen 




Specific Aim 1: 
The first specific aim of this study is to determine whether independently increasing each 
antibody identified will decrease the incidence of malaria. We will begin with four groups of 
healthy humanized female mice.56 Female mice will be used because they are less aggressive, 
smaller, and less expensive than male mice. Mice used will be three weeks old.115 By this age, 
mice can open their eyes, have mobility, and can be successfully removed from their mothers.115 
Female mice reach sexual maturity by the age of six weeks.115 Therefore, female mice between 
Figure 10. Anti-MSP2 fragment in 
complex with 3D7-MSP2.108 
Figure 11. Anti-MSP2 fragment in 
complex with FC27-MSP2.109 
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the ages of three weeks to six weeks will closely represent the target age group for a vaccine in 
humans.115 Purchasing three week old mice will allow them to be viable for this study for three 
weeks. This will ensure that data can still be accurately collected and trials can be repeated if 
necessary.   
The process of humanizing a mouse to be used as a malaria mouse model can be seen in Figure 
12. The specific strain used will be the NOD/SCID/IL2Rγnull strain. This strain has shown to be 
the most effective in previous malaria studies using mouse models.113 In order to replicate the 
immunodeficiency that young children in malaria-endemic areas will be, the mice will be 
injected with liposomal-clodronate formulations.113 This injection will deplete murine phagocytic 
cells, and it has been shown that this produces a mouse model of malaria in which 100% of 





Figure 12. Humanizing a mouse to be used as a mouse model for malaria. 
A humanized mouse is a model where a mouse gene is replaced by the 
human gene. Then, the human protein domain is expressed while the mouse 
protein domain is suppressed in all cells and tissues.110 
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One group will receive an injection of anti-AMA 1 antibodies, the second group will receive 
anti-MSP1 antibodies, the third group will receive anti-MSP2 antibodies, and the fourth group 
will receive an injection of phosphate buffer solution (PBS) to serve as a control group. All 
antibody formulations will be diluted in PBS. These groups and their injections are listed in the 
table below. Each group will include 25 mice, for a total of 100 mice to be used in specific aim 
1. 
 Anti-AMA1 Anti-MSP1 Anti-MSP2 PBS 
Group 1 X   X 
Group 2  X  X 
Group 3   X X 
Group 4    X 
 
The mice will then be placed in a large enclosure with four separate sections for each mouse 
group. The enclosure will be sectioned by a piece of hard plastic containing several small holes. 
Female Anopheles mosquitoes carrying the Plasmodium falciparum parasite will then be released 
into the mouse enclosures. The small holes in the plastic interior walls of the enclosure will be 
large enough for mosquitoes to pass freely through. A representation of this enclosure can be 
seen in Figure 13. 
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After a period of time, the mosquitoes will be collected and the mice will be analyzed for the 
presence of a malaria infection. Blood smears will be collected from each mouse at three 
separate time intervals. Blood smears will first be taken immediately after mice are brought out 
of the enclosure, then again one day later, and finally one week later. Each sample will be stained 
with Giemsa stain, which will give parasites a distinct appearance, as seen in Figure 
14.57Samples will then be microscopically analyzed for the presence of Plasmodium falciparum 
parasites.  
Figure 13. A representation of the 
enclosure that will be used to house 
mouse groups. Mosquitoes will have the 
ability to pass freely through small holes 
in the interior walls separating mouse 
groups. The actual enclosure used will 
be larger and will contain a compartment 
for each mouse group.111 





The DNA from these blood smears will then be extracted and PCR will then be performed to test 
for the presence of parasite nucleic acids.58 If a sample shows the presence of a parasite through 
microscopy or from PCR, that mouse will be considered to have tested positive for malaria 
infection. These results will then be graphed and analyzed to determine the effect of increased 
antibody levels on the incidence of malaria infection.  
Specific Aim 2: 
While specific aim 1 determined the effect of the three antibodies independently, specific aim 2 
will focus on determining the effect of using a combination of antibodies on malaria incidence. 
In this experiment, mice will be divided into 5 groups, each receiving a different combination of 
antibody injections. These combinations will be anti-AMA 1 and anti-MSP1, anti-AMA 1 and 
anti-MSP2, anti-MSP1 and anti-MSP2, and anti-AMA 1, anti-MSP1, and anti-MSP2. The final 
Figure 14. Blood smears stained with Giemsa stain.57 Giemsa stain 
gives parasites a distinct appearance inside the red blood cells, 
giving a clear indication of malaria infection. 
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fifth group will receive an injection of PBS and will serve as the control group. All antibody 
formulations will be diluted in PBS. Each group and their injections are listed in the table below. 
Each group will include 25 mice, for a total of 125 mice to be used in specific aim 2. 
 Anti-AMA 1 Anti-MSP1 Anti-MSP2 PBS 
Group 1 X X  X 
Group 2 X  X X 
Group 3  X X X 
Group 4 X X X X 
Group 5    X 
 
Mice will then be placed in separate attached enclosures, parasite-carrying mosquitoes will be 
released in enclosures, and blood samples from mice will then be taken at three separate time 
intervals as in specific aim 1. Blood smears will then be analyzed using microscopy and PCR as 
before, and results will be graphed and analyzed. 
Specific Aim 3: 
Specific aim 3 will test whether the antibodies analyzed previously can cross the placental barrier 
of a pregnant mother and induce acquired immunity in her fetus. The most effective antibody 
combination, as determined in specific aim 2, will be injected into pregnant female 
NOD/SCID/IL2Rγnull humanized mice. As a control, one group of pregnant mice will be injected 
with only PBS. Each group will contain 25 pregnant mice, for a total of 50 mice. The pregnant 
mice will then carry their pups to term and will give birth naturally. The pups will then be 
permitted to grow and mature normally. At three weeks of age, the pups will be placed in the 
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same enclosure as specified earlier, and female Anopheles mosquitoes carrying the Plasmodium 
parasite will be placed in the enclosure. As before, blood samples will be taken at three different 
time periods and will be analyzed by microscopy and PCR. Results will then be graphed and 
analyzed. 
Proposed Results 
In specific aim 1, I hypothesize that we will find a statistically significant difference between the 
mice with no antibody injection and the mice with anti-AMA1 antibody injection. In addition, I 
predict that a slightly statistically significant difference will be found both between the control 
group and the anti-MSP1 group, and between the control group and the anti-MSP2 group. These 
findings would suggest that anti-AMA1, anti-MSP1, and anti-MSP2 antibodies contributes to 
malaria immunity in some way.  
In specific aim 2, I hypothesize that a slightly significant difference will be found between the 
control group and each group containing two antibody injections (anti-AMA1 and anti-MSP1; 
anti-AMA1 and anti-MSP2; anti-MSP1 and anti-MSP2). In addition, I predict that a very large 
statistically significant difference will be found between the control group and the group 
receiving an injection of all three antibodies. These findings would suggest that the three 
antibodies tested not only contribute to malarial immunity, but that they also work 
synergistically. AMA1, MSP1, and MSP2 are all present of the surface of the parasitic 
merozoite. By adding antibodies specific for each of these antigens to a person's adaptive 
immunity arsenal, the immune system will be more than prepared to fight against all merozoites 
that enter the body if infected by a mosquito. 
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In specific aim 3, I hypothesize that a statistically significant difference will be found between 
the group of mice whose mothers were injected with antibody formulation and the control group. 
This hypothesis is based on the fact that IgG antibodies are capable of passing the placental 
barrier.120 This finding would suggest that the antibody formulation has the ability to cross the 
placental barrier and induce acquired immunity in an unborn fetus. This finding would be 
consistent with a finding from a previous study that suggests that some children born to mothers 
infected with Plasmodium while pregnant are born with B cells capable of secreting IgM and 
IgG antibodies to antigens AMA-1, MSP-1, and MSP-2.121 If these results align with that found 
from the previous study, it would show that Plasmodium falciparum antibodies do cross the 
placenta and activate fetal B and T cells in utero.121 This would be promising for the introduction 
of a malaria vaccine in malaria-endemic countries because the vaccine could target two groups 
(young children and pregnant mothers) rather than just young children.  
Future Studies 
If the results show that the three antibodies tested reduce the incidence of malaria, then the 
antibodies will serve as another possible target for a vaccine candidate. Further study into the 
degree of malaria protection each antibody or a combination of the antibodies produces should 
be done. Experimentation to determine the most effective dosage and concentration of antibodies 
should also take place since too low of a dose could produce ineffective results. 
Other studies should revolve around testing these antibodies' efficacy among various age groups, 
genders, and specific malaria risk groups (such as pregnant women or immunocompromised 
people). The efficacy rate among these different groups is very likely to differ from one another. 
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Another important research route to explore is to elucidate the mechanisms through which these 
antibodies inhibit parasitic infection.  
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